Enfuvirtide
Title: Enfuvirtide
CAS Registry Number: 159519-65-0
Additional Names: Pentafuside
Manufacturers' Codes: DP-178; T-20
Trademarks: Fuzeon (Roche)
Molecular Formula: C204H301N51O64
Molecular Weight: 4491.88
Percent Composition: C 54.55%, H 6.75%, N 15.90%, O 22.80%
Literature References: HIV fusion inhibitor. Synthetic, 36 amino acid peptide corresponding to a region of gp41, the transmembrane subunit of the HIV-1 envelope protein. Prepn and biological activity: D. P. Bolognesi et al., WO 9428920; eidem, US 5464933 (1994, 1995 both to Duke Univ.); C. T. Wild et al., Proc. Natl. Acad. Sci. USA 91, 9770 (1994). Mechanism of action study: R. A. Furuta et al., Nat. Struct. Biol. 5, 276 (1998). Clinical pharmacokinetics: J. M. Kilby et al., AIDS Res. Hum. Retroviruses 18, 685 (2002). Review of development: N. Press et al., Curr. Opin. Anti-Infect. Invest. Drugs 1, 171-178 (1999); of clinical evaluations: A. Pozniak, J. HIV Ther. 6, 91-94 (2001).
Therap-Cat: Antiviral.
Keywords: HIV Fusion Inhibitor; Antiviral.

Others monographs:
3-Methyl-2-butanolMercurous AcetateCoprosterolTricromyl
Potassium FerrocyanideIpidacrineProtoporphyrin IXPro-Urokinase
HypericinHexamethyldisilazaneo-TolidineChrysergonic Acid
2,4-DiaminophenolMetribuzinThiosemicarbazideGallium Oxide
©2016 DrugLead US FDA&EMEA